Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGAV | P06756 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195684 | 0.89 | AURKA (0.44) | ALDH1A1LMNAMAPTCA1CA2 | |
| SCHEMBL7862046 | 0.88 | ITGB3 (0.45) | MAPTCA1CA2MEN1KMT2A | |
| SCHEMBL7864759 | 0.82 | MEN1 (0.48) | LMNAMAPTCA1CA2SMN1; SMN2 | |
| SCHEMBL13715863 | 0.81 | PKM (0.46) | ALDH1A1LMNAMAPTCA1CA2 | |
| SCHEMBL7863164 | 0.80 | MEN1 (0.43) | ALDH1A1LMNAMAPTCA1CA2 | |
| SCHEMBL7856528 | 0.80 | MEN1 (0.43) | LMNAMAPTCA1CA2SMN1; SMN2 | |
| SCHEMBL7856530 | 0.80 | CA1 (0.54) | MAPTCA1CA2MEN1KMT2A | |
| SCHEMBL7864762 | 0.79 | CA1 (0.42) | MAPTCA1CA2MEN1KMT2A | |
| SCHEMBL7864212 | 0.79 | MEN1 (0.41) | ALDH1A1LMNAMAPTCA1CA2 | |
| SCHEMBL6366667 | 0.79 | ITGB3 (0.60) | ALDH1A1CA1CA2L3MBTL1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589972-B2 | Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1147079-A2 | BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-24 | — | — | EP | disclosed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
| WO-2000041469-A2 | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | ALDH1A1 2010/4885LMNA 2949/4885MAPT 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.